IQVIA Holdings Inc (IQV)vsOracle Corporation (ORCL)
IQV
IQVIA Holdings Inc
$183.45
-1.84%
HEALTHCARE · Cap: $29.83B
ORCL
Oracle Corporation
$213.68
-2.84%
TECHNOLOGY · Cap: $703.42B
Smart Verdict
WallStSmart Research — data-driven comparison
Oracle Corporation generates 285% more annual revenue ($64.08B vs $16.63B). ORCL leads profitability with a 25.3% profit margin vs 8.3%. IQV appears more attractively valued with a PEG of 0.72. ORCL earns a higher WallStSmart Score of 69/100 (B-).
IQV
Strong Buy66
out of 100
Grade: B-
ORCL
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+9.1%
Fair Value
$194.83
Current Price
$183.45
$11.38 discount
Intrinsic value data unavailable for ORCL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 42 in profit
Strong operational efficiency at 32.7%
Keeps 25 of every $100 in revenue as profit
Revenue surging 21.7% year-over-year
Earnings expanding 24.5% YoY
Areas to Watch
Weak financial health signals
Distress zone — elevated risk
Expensive relative to growth rate
Trading at 18.3x book value
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bull Case : ORCL
The strongest argument for ORCL centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 25.3% and operating margin at 32.7%. Revenue growth of 21.7% demonstrates continued momentum.
Bear Case : IQV
The primary concerns for IQV are Piotroski F-Score, Altman Z-Score.
Bear Case : ORCL
The primary concerns for ORCL are PEG Ratio, Price/Book, Piotroski F-Score. A P/E of 44.0x leaves little room for execution misses. Debt-to-equity of 4.21 is elevated, increasing financial risk.
Key Dynamics to Monitor
IQV profiles as a value stock while ORCL is a growth play — different risk/reward profiles.
ORCL carries more volatility with a beta of 1.54 — expect wider price swings.
ORCL is growing revenue faster at 21.7% — sustainability is the question.
IQV generates stronger free cash flow (491M), providing more financial flexibility.
Bottom Line
ORCL scores higher overall (69/100 vs 66/100), backed by strong 25.3% margins and 21.7% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Oracle Corporation
TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA
Oracle is an American multinational computer technology corporation headquartered in Austin, Texas. The company was formerly headquartered in Redwood Shores, California until December 2020 when it moved its headquarters to Texas. The company sells database software and technology, cloud engineered systems, and enterprise software products, particularly its own brands of database management systems.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?